Company Announcements

New Sustainability Committee of the Board

Source: RNS
RNS Number : 6830M
AstraZeneca PLC
23 September 2021

23 September 2021 07:00 BST


AstraZeneca establishes new Sustainability Committee of the Board


AstraZeneca PLC announced today that the Board has established a Sustainability Committee. The Committee has been constituted to monitor the execution of the Company's sustainability strategy, to oversee the communication of the Company's sustainability activities with its stakeholders and to provide input to the Board and other Board Committees on sustainability matters. The terms of reference of the Committee are available at


The members of the Committee, all of whom are Non-Executive Directors of the Company, are Nazneen Rahman (Chairman of the Committee), Sheri McCoy, Andreas Rummelt and Marcus Wallenberg. These appointments take effect and the Committee will operate from 1 October 2021.


The establishment of a Sustainability Committee is a natural evolution of the Company's previous governance arrangement of having a single Board member with responsibility for overseeing sustainability matters on behalf of the Board.


Further information about sustainability at AstraZeneca is available at



AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit and follow the Company on Twitter @AstraZeneca.



For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.



Adrian Kemp
Company Secretary

AstraZeneca PLC


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.